Good MorningEquity markets were able to claw their way higher on Wednesday despite a hot read on inflation. The August CPI came in hotter than expected at the headline and core levels due to the rise of oil prices and threatens to push the Fed into another interest rate hike. The S&P 500 moved up less than 0.25% on the news, but the fact gains were made shows the market still does not believe inflation remains a problem.
The market seems to be heading into a bull trap. The S&P 500 is in rally mode despite the rising chance for additional interest rate hikes, and it is seriously mispricing the odds. As it is, the market has yet to price in another hike, and there could be more than 1 on the way. The price of WTI is up another 2.5% so far in September, the cause of hot inflation, and it is likely to continue rising. The next FOMC policy announcement is 1 week away and poses a significant threat to bullish traders. Featured: Wall Street’s quietly buying these 3 AI infrastructure plays (Ad) 
|
Technology | |
AI is hot right now and driving outsized expectations for many stocks today. One way to tell which companies have the best chances of success is to see which ones the institutions are buying. Institutional buying is significant and should be watched for many reasons. Most importantly, they have th... Read the Full Story |
|
From Our Partners | | BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid.
The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. | | Get the name, the ticker, and exactly how to buy it |
|
Auto/Tires/Trucks | |
With Tesla Inc (NASDAQ: TSLA) shares having already rallied close to 200% this year, many investors will understandably be wary about chasing the bid. It’s always nice to feel like you’re getting shares at a discount whenever you decide to buy, but unless you’re one of the most a... Read the Full Story |
|
Energy | |
Based out of Canada, Enbridge Inc. (NYSE: ENB) operates the world's longest crude oil and liquids transportation system, totaling 17,809 miles of active pipeline. While it also has core businesses in the natural gas pipelines, gas utilities and storage and renewable energy segment, it still collec... Read the Full Story |
|
From Our Partners | | See the Signals Most Traders Miss
We monitor subtle shifts in order flow, volume patterns, and early trend behavior.
Stock News Trends highlights moves long before they hit mainstream screens. | | Join Free — Start Tracking Early Market Data |
|
Finance | |
Are you a REIT investor looking for diversification in your passive income streams? REITs are terrific vehicles for gaining exposure to the real estate market without going through the hassle of purchasing property. They're also imperfect assets with certain risks. A REIT alternative can mitigate ... Read the Full Story |
|
Retail/Wholesale | |
Kroger (NYSE: KR) is no exciting stock, but that is the point. Kroger isn’t an exciting stock, but it is a blue-chip player in consumer staples; it has solid revenue and earnings, sustainable cash flow, and pays a healthy dividend. To put its non-exciting quality into better perspective, Kro... Read the Full Story |
|
From Our Partners | | With OpenAI and Anthropic moving closer to the IPO spotlight, AI excitement could spill into several public-market sectors this summer - and most investors may chase the obvious names too late.
A free report identifies 7 stocks positioned around themes that could matter most this summer: AI infrastructure, energy demand, travel, entertainment, home improvement, and more. Built for a market where leadership may rotate quickly. | | Download 7 Best Stocks to Own in Summer 2026 for free |
|
Retail/Wholesale | |
Snacks and cleaning supplies aren’t the only thing on sale at Dollar General Corporation (NYSE:DG).
Last week, shares of the discount retailer fell to their lowest level since May 2019 following a dreadful second quarter earnings report. Like a bottle of generic bleach, the move erased all ... Read the Full Story |
|
Energy | |
Shell plc (NYSE: SHEL) recently cleared price resistance above $63.69, trending higher in heavier-than-normal volume as the broader energy sector moves higher.
While the recent price move is encouraging, the dividend is also an attractive feature of Shell’s stock.
MarketBeat’s Shell... Read the Full Story |
|
Technology | |
Having easily outpaced the S&P 500 all year, Apple Inc (NASDAQ: AAPL) shares are suddenly finding themselves playing catchup against the benchmark index. Since hitting an all-time high at the end of July they’ve become noticeably cooler, and the bulls will be getting nervous. The stock i... Read the Full Story |
|
Technology | |
What goes down must come up. This has certainly been the mantra for many U.S. stocks in 2023. The most prominent example is the technology sector. Thanks to the ceremonious arrival of artificial intelligence (AI), tech stocks are getting bid up like it's 1999. As the classic Prince hit goes, it ma... Read the Full Story |
|
Finance | |
The real estate market in the United States is undergoing a tantrum, as neither builders nor would-be buyers are happy with how mortgage rates are behaving today. Shares of Realty Income (NYSE: O) have declined by 14.7% during the past two months... Why?
As the FED seeks to combat the wild inflat... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey. | | View Today's Stock Pick |
|
